Company / Operating Cash Flow
Matinas BioPharma Holdings, Inc. Operating Cash Flow History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$15.9M
FY2024
5-year range
-$19.2M / -$15.2M
FY2020-FY2024
Trend
+17.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 10 years, ranging from -$19M in FY2023 to -$6M in FY2016.
Based on SEC 10-K filings.
-$16M in FY2024.
Declined from -$15M to -$16M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow increased 17.1% year-over-year.
- Peak operating cash flow was recorded in FY2016.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$15.9M | +17.1% |
| FY2023 | -$19.2M | -25.8% |
| FY2022 | -$15.2M | +0.0% |
| FY2021 | -$15.2M | +12.3% |
| FY2020 | -$17.4M | -68.3% |
| FY2019 | -$10.3M | +9.9% |
| FY2018 | -$11.5M | -46.6% |
| FY2017 | -$7.8M | -27.7% |
| FY2016 | -$6.1M | +21.7% |
| FY2015 | -$7.8M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026